Arovella Therapeutics Limited (ALA.AX)
AUD 0.08
(1.25%)
AUD 0.08
(1.25%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 | 17 Thousand AUD | -95.81% |
| 2023 | 405.89 Thousand AUD | 37.22% |
| 2022 | 295.81 Thousand AUD | 14.95% |
| 2021 | 257.34 Thousand AUD | -51.69% |
| 2020 | 532.69 Thousand AUD | -56.3% |
| 2019 | 1.21 Million AUD | 186.26% |
| 2018 | 425.86 Thousand AUD | -94.1% |
| 2017 | 7.22 Million AUD | 24.81% |
| 2016 | 5.78 Million AUD | 2.86% |
| 2015 | 5.62 Million AUD | -34.96% |
| 2014 | 8.64 Million AUD | 113.8% |
| 2013 | 4.04 Million AUD | 3.48% |
| 2012 | 3.9 Million AUD | 30.13% |
| 2011 | 3 Million AUD | 21031.19% |
| 2010 | 14.21 Thousand AUD | -26.55% |
| 2009 | 19.35 Thousand AUD | -99.84% |
| 2008 | 11.85 Million AUD | 24.7% |
| 2007 | 9.5 Million AUD | 14.03% |
| 2006 | 8.33 Million AUD | 2.03% |
| 2005 | 8.17 Million AUD | 72.22% |
| 2004 | 4.74 Million AUD | 3271.18% |
| 2003 | 140.76 Thousand AUD | 0.0% |
| 2002 | - AUD | 0.0% |
| 2001 | - AUD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 8500.00 AUD | -99.13% |
| 2024 Q3 | 4250.00 AUD | -50.0% |
| 2024 FY | 17 Thousand AUD | -95.81% |
| 2024 Q4 | 4250.00 AUD | 0.0% |
| 2024 Q1 | 971.81 Thousand AUD | 3593.69% |
| 2023 Q3 | 13.15 Thousand AUD | -96.53% |
| 2023 Q2 | 379.58 Thousand AUD | -46.85% |
| 2023 Q1 | 714.17 Thousand AUD | 161.39% |
| 2023 FY | 405.89 Thousand AUD | 37.22% |
| 2023 Q4 | 26.31 Thousand AUD | 100.0% |
| 2022 Q3 | 136.6 Thousand AUD | 504.71% |
| 2022 Q4 | 273.21 Thousand AUD | 100.0% |
| 2022 FY | 295.81 Thousand AUD | 14.95% |
| 2022 Q1 | 11.29 Thousand AUD | -23.71% |
| 2022 Q2 | 22.59 Thousand AUD | 99.99% |
| 2021 Q2 | 242.54 Thousand AUD | 37.95% |
| 2021 Q3 | 319.03 Thousand AUD | 31.54% |
| 2021 Q4 | 14.8 Thousand AUD | -95.36% |
| 2021 FY | 257.34 Thousand AUD | -51.69% |
| 2021 Q1 | 175.82 Thousand AUD | 7.95% |
| 2020 FY | 532.69 Thousand AUD | -56.3% |
| 2020 Q2 | 369.81 Thousand AUD | 92.99% |
| 2020 Q1 | 191.62 Thousand AUD | -51.62% |
| 2020 Q3 | 106.14 Thousand AUD | -71.3% |
| 2020 Q4 | 162.87 Thousand AUD | 53.44% |
| 2019 Q3 | 198.05 Thousand AUD | -53.65% |
| 2019 Q2 | 427.33 Thousand AUD | -0.0% |
| 2019 Q1 | 427.33 Thousand AUD | 958.84% |
| 2019 Q4 | 396.1 Thousand AUD | 100.0% |
| 2019 FY | 1.21 Million AUD | 186.26% |
| 2018 Q4 | 40.35 Thousand AUD | -5.9% |
| 2018 Q2 | 201.71 Thousand AUD | -0.0% |
| 2018 FY | 425.86 Thousand AUD | -94.1% |
| 2018 Q1 | 201.71 Thousand AUD | 111.79% |
| 2018 Q3 | 42.88 Thousand AUD | -78.74% |
| 2017 Q4 | -1.71 Million AUD | -191.25% |
| 2017 FY | 7.22 Million AUD | 24.81% |
| 2017 Q3 | 1.87 Million AUD | 859.74% |
| 2017 Q2 | 195.41 Thousand AUD | 0.0% |
| 2017 Q1 | 195.41 Thousand AUD | -87.07% |
| 2016 Q1 | 1.41 Million AUD | 0.88% |
| 2016 FY | 5.78 Million AUD | 2.86% |
| 2016 Q4 | 1.51 Million AUD | 0.0% |
| 2016 Q2 | 1.41 Million AUD | -0.0% |
| 2016 Q3 | 1.51 Million AUD | 6.48% |
| 2015 FY | 5.62 Million AUD | -34.96% |
| 2015 Q4 | 1.4 Million AUD | 0.0% |
| 2015 Q3 | 1.4 Million AUD | -7.61% |
| 2015 Q2 | 1.52 Million AUD | 0.0% |
| 2015 Q1 | 1.52 Million AUD | 21.26% |
| 2014 Q2 | 3.12 Million AUD | 0.0% |
| 2014 Q1 | 3.12 Million AUD | 216.99% |
| 2014 FY | 8.64 Million AUD | 113.8% |
| 2014 Q4 | 1.25 Million AUD | 0.0% |
| 2014 Q3 | 1.25 Million AUD | -59.77% |
| 2013 Q1 | 1.04 Million AUD | 0.0% |
| 2013 Q3 | 984.56 Thousand AUD | -6.08% |
| 2013 Q4 | 984.56 Thousand AUD | 0.0% |
| 2013 FY | 4.04 Million AUD | 3.48% |
| 2013 Q2 | 1.04 Million AUD | 0.0% |
| 2012 FY | 3.9 Million AUD | 30.13% |
| 2011 FY | 3 Million AUD | 21031.19% |
| 2010 FY | 14.21 Thousand AUD | -26.55% |
| 2009 FY | 19.35 Thousand AUD | -99.84% |
| 2008 FY | 11.85 Million AUD | 24.7% |
| 2007 FY | 9.5 Million AUD | 14.03% |
| 2006 FY | 8.33 Million AUD | 2.03% |
| 2005 FY | 8.17 Million AUD | 72.22% |
| 2004 FY | 4.74 Million AUD | 3271.18% |
| 2003 FY | 140.76 Thousand AUD | 0.0% |
| 2002 FY | - AUD | 0.0% |
| 2001 FY | - AUD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| AdAlta Limited | 1.73 Million AUD | 99.022% |
| Acrux Limited | 5.09 Million AUD | 99.666% |
| Race Oncology Limited | 4 Million AUD | 99.575% |
| Biome Australia Limited | 13 Million AUD | 99.869% |
| Botanix Pharmaceuticals Limited | 601.82 Thousand AUD | 97.175% |
| BTC Health Limited | 16.36 Thousand AUD | -3.912% |
| Chimeric Therapeutics Limited | 7.45 Million AUD | 99.772% |
| CSL Limited | 22.41 Billion AUD | 100.0% |
| Clarity Pharmaceuticals Ltd | 11.5 Million AUD | 99.852% |
| Clinuvel Pharmaceuticals Limited | 88.17 Million AUD | 99.981% |
| EZZ Life Science Holdings Limited | 66.44 Million AUD | 99.974% |
| Hexima Limited | - AUD | -Infinity% |
| Immutep Limited | 3.5 Million AUD | 99.515% |
| Memphasys Limited | 60 Thousand AUD | 71.667% |
| Neuren Pharmaceuticals Limited | 231.92 Million AUD | 99.993% |
| Noxopharm Limited | 2.4 Million AUD | 99.292% |
| Prescient Therapeutics Limited | 3.71 Million AUD | 99.542% |
| Radiopharm Theranostics Limited | 299.22 Thousand AUD | 94.319% |
| Starpharma Holdings Limited | 8.28 Million AUD | 99.795% |
| Tissue Repair Ltd | 152.24 Thousand AUD | 88.833% |
| Biotron Limited | - AUD | -Infinity% |
| Alterity Therapeutics Limited | 4.01 Million AUD | 99.577% |
| Anatara Lifesciences Ltd | - AUD | -Infinity% |
| Bio-Gene Technology Limited | 18.32 Thousand AUD | 7.205% |
| Zelira Therapeutics Limited | 94.95 Thousand AUD | 82.096% |
| Patrys Limited | 1.39 Million AUD | 98.781% |
| Orthocell Limited | 5.31 Million AUD | 99.68% |
| Imugene Limited | - AUD | -Infinity% |
| PYC Therapeutics Limited | 22.05 Million AUD | 99.923% |
| Proteomics International Laboratories Limited | 892.14 Thousand AUD | 98.094% |
| Cynata Therapeutics Limited | 2.31 Million AUD | 99.266% |
| Nanollose Limited | 12.5 Thousand AUD | -35.989% |
| Invex Therapeutics Ltd | 1.21 Million AUD | 98.598% |
| NeuroScientific Biopharmaceuticals Limited | - AUD | -Infinity% |
| Amplia Therapeutics Limited | 4.45 Million AUD | 99.618% |
| Island Pharmaceuticals Limited | 1.25 Million AUD | 98.642% |
| Nyrada Inc. | - AUD | -Infinity% |
| Telix Pharmaceuticals Limited | 496.65 Million AUD | 99.997% |
| Dimerix Limited | 583.47 Thousand AUD | 97.086% |
| PharmAust Limited | - AUD | -Infinity% |
| AnteoTech Limited | 460.39 Thousand AUD | 96.308% |
| Paradigm Biopharmaceuticals Limited | 65.8 Thousand AUD | 74.164% |
| Recce Pharmaceuticals Ltd | - AUD | -Infinity% |
| Avecho Biotechnology Limited | 473.55 Thousand AUD | 96.41% |
| Actinogen Medical Limited | 9.93 Million AUD | 99.829% |
| Immuron Limited | 4.9 Million AUD | 99.653% |
| Argenica Therapeutics Limited | 2.59 Million AUD | 99.346% |